ClinicalTrials.gg
CompletedNCT00431275Updated Jun 6, 2012

Study to Compare Two Formulations of CP-675,206 Monoclonal Antibody

A Phase 1 interventional study of CP-675,206 and CP-675,206 in Melanoma, sponsored by AstraZeneca. Completed at 8 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2012-06-06.

Sponsored by AstraZeneca · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
85
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing tremelimumab in Melanoma — none open to participants now, none under way, none of them phase 3. tremelimumab · Melanoma.

Enrollment
4th of 12
85 · median 51
Started
2006
with 2 others
Phase 1
5 of 12
none open now
Registered
5th of 12
by date
Lead sponsor
6 of 12
AstraZeneca

Among the 12 studies testing tremelimumab in Melanoma, this one is the 4th largest by enrollment, is one of 3 that started in 2006, is one of 5 in phase 1, and was the 5th registered.

Melanoma

3,372 studies on the registry are indexed under Melanoma; 580 are open to participants now.

Browse Melanoma studies →

Open to participants now

None of the 12 studies testing tremelimumab in Melanoma is open now. The open studies under Melanoma, anywhere →

About tremelimumab

tremelimumab: first FDA approval 2022 (IMJUDO), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 467 Melanoma studies recruiting now, 380 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing tremelimumab in Melanoma as a file.
02

Study summary

This is an open-label, 2-arm study in which patients are randomized to receive either the formulation that is being used in clinical trials or the formulation that will be used when if the drug becomes commercially available. The purpose of this study is to compare the pharmacokinetics of the two formulations.

03

Conditions studied

  • Melanoma

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Stage III or Stage IV melanoma
  • No evidence of disease following resection of melanoma lesions
  • Recovered from all prior surgical or treatment-related toxicities

Exclusion criteria

Exclusion Criteria:

  • History of chronic inflammatory or disease
  • History of inflammatory bowel disease
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
85 participants (actual)

Study arms

  • Experimental
    Commercial Formulation

    Commercial Formulation

    Drug: CP-675,206

  • Experimental
    Current Formulation

    Current Formulation

    Drug: CP-675,206

Interventions

  • CP-675,206 15 mg/kg iv single dose on Day 1

    Also known as: anti-CTLA4 human monoclonal antibody

  • CP-675,206 15 mg/kg iv single dose on Day 1

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics: maximum plasma concentration of CP-675,206

    Time frame: 1 hour

  2. Pharmacokinetics: AUC, defined as the area under the concentration -time curve

    Time frame: Time 0 to Day 85

Secondary outcomes

  1. Human-anti-human antibodies

    Time frame: 1 year

  2. Adverse events

    Time frame: 1 year

  3. Safety laboratory tests

    Time frame: 1 year

  4. Proportion of patients alive and free of disease at 1 year

    Time frame: 1 year

07

Study locations

8 sites
  • Research Site
    Scottsdale, Arizona 85260, United States
  • Research Site
    Aurora, Colorado 80010, United States
  • Research Site
    Aventura, Florida 33180, United States
  • Research Site
    Miami Beach, Florida 33140, United States
  • Research Site
    Atlanta, Georgia 30322, United States
  • Research Site
    New York, New York 10016, United States
  • Research Site
    Philadelphia, Pennsylvania 19104, United States
  • Research Site
    Pittsburgh, Pennsylvania 15213, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2006, a primary completion of Feb 2008 and a completion of Feb 2008. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2007
First posted
Feb 5, 2007
Start
Jun 2006
Primary completionActual
Feb 2008
CompletionActual
Feb 2008
Last update
Jun 6, 2012
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2012, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00431275
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Feb 5, 2007
Start date
Jun 2006
Primary completion
Feb 2008
Completion
Feb 2008
Last update
Jun 6, 2012

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2012. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tremelimumab

Start the discussion